Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2010

View Archived Issues

MicroRNA expression profiles associated with malignancy potential of pancreatic cystic tumors

Phase I and II data reported on blinatumomab in hematological cancers

Intratumoral TG-4023 gene therapy is feasible in patients with liver cancer

Aliskiren/amlodipine combination effective in hypertension

UDPGT 1-4 gene polymorphism affects lamotrigine pharmacokinetics

Evatanepag accelerates fracture healing in phase II trial

TRUST trial further explores efficacy and safety of corifollitropin alfa

New apoptosis-inducing agents discovered at Brock University

Nycomed presents new chemokine CCR3 receptor modulators

Roche claims new JNK inhibitors with anti-inflammatory potential

New cannabinoid CB2 receptor ligands in development at Abbott

Infinity and Intellikine to codevelop INK-1197 and other PI3K inhibitors

FDA approves Beech Tree Labs' IND for BTL-TML-HSV

Achillion patents novel compounds to treat hepatitis C

Winston Labs submits NDA for Civanex for osteoarthritis signs in the U.S.

Nile Therapeutics doses last patient in phase II trial of CD-NP in ADHF

FDA approves Atir IND in patients with mismatched bone marrow transplant

E.C. approves Reyataz capsules for HIV-1 in pediatric patients

Fornix completes sale of allergy division to ALK-Abello

Oramed and sanofi-aventis enter agreement for oral insulin capsules

Stem cell-based therapy in development for corneal vision impairment

Preclinical data reported for intravenous Restanza for hospital use

Neoprobe begins third phase III trial of Lymphoseek

AVI BioPharma applies for IND for AVI-4658 in DMD

Cellceutix completes animal safety pharmacology studies required by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...